Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
Receive an email update when we add a new DUCHENNE MUSCULAR DYSTROPHY article.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress on November 13, 2018 at 4:05 am
Recent and Upcoming Corporate Highlights Multiple sites open for enrollment for the Phase 3 PolarisDMD clinical trial evaluating edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) The ... […]
- Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update on November 13, 2018 at 3:00 am
“We are pleased to have made significant progress toward our goal of bringing meaningful treatments to patients with Duchenne muscular dystrophy,” said Ilan Ganot, Chief Executive ... […]
- Duchenne UK backs Evox dystrophin delivery project on November 13, 2018 at 2:46 am
Oxford University spin-out Evox Therapeutics has won a £656,000 ($858,000) grant from a UK medical charity to test its large-molecule delivery technology in Duchenne muscular dystrophy (DMD). Duchenne ... […]
- Evox bags grant from Duchenne UK to engineer exosomes on November 13, 2018 at 1:15 am
“We are delighted to be working with Evox to advance this potentially exciting work to help in the field of Duchenne muscular dystrophy,” added Emily Crossley and Alex Johnson, co-chief executives of ... […]
- Evox Therapeutics Wins Funding From Duchenne UK to Explore Exosome-Mediated Delivery of Dystrophin on November 12, 2018 at 10:00 pm
The grant will be invested to support exploration of the Company's exosome-based therapeutic platform to deliver either full-length dystrophin or its shorter variants in pre-clinical models of Duchenn... […]
- How Target landed Lupita, the Kickstarted, Hispanic answer to Elf on the Shelf (Video) on November 12, 2018 at 9:06 am
Leslie Guzman took early retirement from P&G in 2015 after a 20-year career with the company to spend more time with her son Diego, who has Duchenne muscular dystrophy. She also took that time to crea... […]
- Global Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends (2018-2023): Analysis by Therapeutic Approach on November 9, 2018 at 7:40 am
The "Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends Analysis Report By Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy) And Segment Forecasts, 2018 ... […]
- Duchenne Muscular Dystrophy (DMD) Drugs - Worldwide Markets to 2023 - ResearchAndMarkets.com on November 9, 2018 at 4:01 am
The "Duchenne Muscular Dystrophy (DMD) Drugs Market Size, Share & Trends Analysis Report By Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy) And Segment Forecasts, 2018 - 20... […]
- Parent Project Muscular Dystrophy Designates Children's Hospital of Wisconsin a Certified Duchenne Care Center on November 6, 2018 at 7:22 am
HACKENSACK, N.J., Nov. 6, 2018 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), named the Neuromuscul... […]
via Bing News